EMA issues semaglutide warning

Country

Netherlands

The European Medicines Agency is to update the side effect profile for semaglutide following evidence from epidemiological studies that use of the drug is associated with a very rare eye condition known as non-arteritic anterior ischaemic optic neuropathy (NAION). This may cause loss of vision. The decision was announced on 6 June and will affect the labelling of three approved semaglutide products, Ozempic, Rybelsus and Wegovy. All three are produced by Novo Nordisk A/S and are on the market in the EU.